Royalty Pharma (NASDAQ:RPRX) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Royalty Pharma (NASDAQ:RPRXGet Free Report) released its earnings results on Thursday. The biopharmaceutical company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02, Zacks reports. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The firm had revenue of $568.00 million for the quarter, compared to analyst estimates of $671.45 million. During the same period in the prior year, the firm earned $1.60 earnings per share.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX traded up $0.12 during trading on Friday, hitting $28.09. 2,879,803 shares of the company were exchanged, compared to its average volume of 2,762,326. The firm’s fifty day moving average price is $29.15 and its 200 day moving average price is $28.58. The company has a debt-to-equity ratio of 0.61, a current ratio of 7.90 and a quick ratio of 7.90. The company has a market cap of $16.78 billion, a price-to-earnings ratio of 14.86 and a beta of 0.47. Royalty Pharma has a 1 year low of $25.92 and a 1 year high of $35.09.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 2.99%. The ex-dividend date is Thursday, May 16th. Royalty Pharma’s dividend payout ratio is presently 44.44%.

Analyst Ratings Changes

RPRX has been the topic of several research analyst reports. Bank of America cut their target price on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, April 12th. StockNews.com lowered Royalty Pharma from a “buy” rating to a “hold” rating in a report on Friday. JPMorgan Chase & Co. decreased their target price on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research report on Tuesday, February 20th. Finally, The Goldman Sachs Group dropped their price objective on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.75.

Read Our Latest Stock Analysis on RPRX

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Featured Stories

Earnings History for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.